tetano
Editor, Senior Moderator
Infect Dis Ther
. 2023 Mar 16.
doi: 10.1007/s40121-023-00782-5. Online ahead of print.
Safety and Effectiveness of Molnupiravir (LAGEVRIO[SUP]®[/SUP]) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
Masahiro Kimata[SUP] 1 [/SUP], Asuka Watanabe[SUP] 2 [/SUP], Yukiko Yanagida[SUP] 3 [/SUP], Daisuke Kinoshita[SUP] 2 [/SUP], Shinichiroh Maekawa[SUP] 2 [/SUP]
Affiliations
Abstract
Introduction: Molnupiravir is an oral antiviral drug that received special approval for emergency use in Japan on December 24 2021 for infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This post-marketing surveillance (PMS) is underway to investigate the safety and effectiveness of molnupiravir in daily clinical practice in Japan. The interim PMS data collected from December 27 2021 to June 15 2022 are reported in this publication.
Methods: This survey included adult Japanese patients treated with molnupiravir. For safety, adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by the composite endpoint of (1) hospitalization or (2) death in outpatients and by the composite endpoint of (3) death or (4) initiation of oxygen administration/mechanical ventilation in inpatients hospitalized for any reasons and without oxygen administration at the start of molnupiravir administration. The observation period was through 29 days from the start of molnupiravir administration.
Results: Of the 1031 patients in the safety analysis set, 68 (6.60%) patients reported ADRs and four (0.39%) patients reported serious ADRs. The main ADRs observed were diarrhoea [26 patients (2.52%)], rash [six patients (0.58%)], dizziness [five patients (0.48%)], and faeces soft [four patients (0.39%)]. In the effectiveness analysis from the start date of molnupiravir administration to day 29, there were 16/612 (2.61%) hospitalizations and no deaths. Oxygen administration was newly initiated in 9/199 (4.52%) inpatients after the initiation of molnupiravir administration; 2/199 (1.01%) inpatients died.
Conclusion: This interim analysis of molnupiravir in daily clinical practice use in Japan supports the safety and effectiveness profile of molnupiravir under pandemic conditions in which Omicron was the dominant SARS-CoV-2 variant. The results of this PMS will provide valuable information for daily clinical practice use.
Keywords: COVID-19; Japan; Molnupiravir; Post-marketing; Safety.
. 2023 Mar 16.
doi: 10.1007/s40121-023-00782-5. Online ahead of print.
Safety and Effectiveness of Molnupiravir (LAGEVRIO[SUP]®[/SUP]) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
Masahiro Kimata[SUP] 1 [/SUP], Asuka Watanabe[SUP] 2 [/SUP], Yukiko Yanagida[SUP] 3 [/SUP], Daisuke Kinoshita[SUP] 2 [/SUP], Shinichiroh Maekawa[SUP] 2 [/SUP]
Affiliations
- PMID: 36928787
- DOI: 10.1007/s40121-023-00782-5
Abstract
Introduction: Molnupiravir is an oral antiviral drug that received special approval for emergency use in Japan on December 24 2021 for infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This post-marketing surveillance (PMS) is underway to investigate the safety and effectiveness of molnupiravir in daily clinical practice in Japan. The interim PMS data collected from December 27 2021 to June 15 2022 are reported in this publication.
Methods: This survey included adult Japanese patients treated with molnupiravir. For safety, adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by the composite endpoint of (1) hospitalization or (2) death in outpatients and by the composite endpoint of (3) death or (4) initiation of oxygen administration/mechanical ventilation in inpatients hospitalized for any reasons and without oxygen administration at the start of molnupiravir administration. The observation period was through 29 days from the start of molnupiravir administration.
Results: Of the 1031 patients in the safety analysis set, 68 (6.60%) patients reported ADRs and four (0.39%) patients reported serious ADRs. The main ADRs observed were diarrhoea [26 patients (2.52%)], rash [six patients (0.58%)], dizziness [five patients (0.48%)], and faeces soft [four patients (0.39%)]. In the effectiveness analysis from the start date of molnupiravir administration to day 29, there were 16/612 (2.61%) hospitalizations and no deaths. Oxygen administration was newly initiated in 9/199 (4.52%) inpatients after the initiation of molnupiravir administration; 2/199 (1.01%) inpatients died.
Conclusion: This interim analysis of molnupiravir in daily clinical practice use in Japan supports the safety and effectiveness profile of molnupiravir under pandemic conditions in which Omicron was the dominant SARS-CoV-2 variant. The results of this PMS will provide valuable information for daily clinical practice use.
Keywords: COVID-19; Japan; Molnupiravir; Post-marketing; Safety.